Ospomyv (Denosumab)
Brand Names: Ospomyv
Methodology & AI Transparency ⓘ
Ospomyv (Denosumab) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2025-11-11 designates Ospomyv (NDC 83457-012, registered by Cordavis Limited) as a prescription brand-name rank ligand inhibitor formulation of Denosumab.
- 2 Real-world patient consensus: Commercial Ospomyv monograph (60 mg/mL Injection, Solution) cross-indexed with generic Denosumab for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $40.90 discount cash to $108.38 walk-in retail (NADAC $0.4500/unit).
- 4 Top reported side effects / signs: Most commonly reported Ospomyv (Denosumab) tolerability events: nausea (8.2%), headache (6.9%), dizziness (5%).
Ask our AI Specialists anything about Ospomyv (Denosumab)
Ospomyv (Denosumab) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2025-11-11 designates Ospomyv (NDC 83457-012, registered by Cordavis Limited) as a prescription brand-name rank ligand inhibitor formulation of Denosumab. Supplied across 60 mg/mL Injection, Solution; Response-guided Denosumab dose modification under follow-up, Ospomyv is utilized in Ospomyv is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high.
Clinical pharmacology for Ospomyv is driven by Denosumab acting within rank ligand inhibitor signaling cascades with class-characteristic hepatorenal disposition. Distributed across 60 mg/mL Injection, Solution; Response-guided Denosumab dose modification under follow-up (NDC 83457-012; registered by Cordavis Limited), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $40.90 to $108.38.
Systemic exposure to Ospomyv (Denosumab) reflects Complete (~100%) parenteral systemic delivery for Ospomyv (Denosumab) (60 mg/mL Injection, Solution) absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar ospomyv (denosumab) conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 6–14 hour t½ intervals for Ospomyv (Denosumab) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after ospomyv (denosumab) administration response profile).
Dosing protocols (60 mg/mL Injection, Solution or Response-guided Denosumab dose modification under follow-up) balance efficacy (89.00% patient satisfaction across 19 logs) against nausea (8.2% of reports), headache (6.9% of reports), fatigue (5.4% of reports), with strict avoidance in history of severe allergic sensitivity to ospomyv (denosumab) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2025-11-11 denosumab labeling.
Verify medication reconciliation lists so Ospomyv (Denosumab) is not inadvertently duplicated with another rank ligand inhibitor.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Ospomyv (Denosumab) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Ospomyv (Denosumab) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2025-11-11 Denosumab labeling
Logged Side-Effect Incidence (19 Reports)
Ospomyv (Denosumab) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ospomyv (Denosumab))
Human clinical trial evidence for Ospomyv (Denosumab) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Ospomyv (Denosumab) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4500/unit (~$13.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $108.38 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $40.90 / mo | View logs ↓ |
Ospomyv (Denosumab) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ospomyv (Denosumab) RxNorm Concept ID | 2725502 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $108.38 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $40.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ospomyv (Denosumab) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Ospomyv (Denosumab) integrating DailyMed SPL (2025-11-11), CMS NADAC ($0.4500/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ospomyv (Denosumab) community threads and patient logs by age, biological sex, dosage, and treatment duration.